检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:杨艳[1] YANG Yan(Department of Fundas Diseases,Cangzhou Eye Hospital,Cangzhou,Hebei 061000,China)
出 处:《检验医学与临床》2018年第7期967-969,共3页Laboratory Medicine and Clinic
摘 要:目的探讨532nm激光治疗视网膜静脉阻塞(RVO)的临床疗效。方法选取2015年2月至2017年2月该院治疗的78例RVO患者78眼,其中视网膜中央静脉阻塞(CRVO)36眼,视网膜分支静脉阻塞(BRVO)42眼,采用532nm激光治疗并观察患者的治疗效果。结果 78眼经治疗后,总有效率为88.46%,其中CRVO和BRVO治疗总有效率分别为83.33%和92.86%,比较差异无统计学意义(P>0.05);患者治疗后视力较治疗前明显提高,差异有统计学意义(P<0.05);患者治疗后视网膜循环时间较治疗前明显降低,差异有统计学意义(P<0.05);患者治疗前后血浆黏度、纤维蛋白原、红细胞沉降率及红细胞聚集指数比较差异无统计学意义(P>0.05);治疗期间均无并发症发生。结论 532nm激光治疗RVO有较好的疗效,有助于患者视力恢复,减少新生血管形成,值得临床推广使用。Objective To investigate the clinical efficacy of 532 nm laser in the treatment of retinal vein occlusion(RVO).Methods A total of 78 cases(78 eyes)of RVO patients treated in the hospital from February 2015 to February 2017 selected,36 eyes of them with central retinal vein occlusion(CRVO)and 42 eyes with branch retinal vein occlusion(BRVO),the clinical efficacy after 532 nm laser treatment were compared.Results The total effective rate was 88.46%,and the effective rates of CRVO and BRVO were 83.33%and 92.86%,respectively,no significant difference found between effective rates of CRVO and BRVO(P>0.05).There were significant improvement in visual acuity in both groups after treatment(P<0.05).The retinal circulation time was lower than that before treatment,the difference was statiscally significant(P<0.05).While there were no significant difference found in plasma viscosity,fibrinogen,erythrocyte sedimentation rate and erythrocyte aggregation index(P>0.05).No complications occured during the trerapy.Conclusion There is certain effect of 532 nm laser treatment in RVO therapy,it can help patients′recovery of visual acuity and reduction of neovascularization.It deserves wider clinical application.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.13